Skip to main content
Article thumbnail
Location of Repository

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

By Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati


Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions with the protein. Resulting me-too drugs have shown favorable pharmacokinetic properties and appear drug-like but, as expected, most have a highly similar interaction with IN to that of raltegravir. We propose that, based upon conclusions drawn from our docking studies illustrated herein, most of these me-too MK-0518 analogues may experience a low success rate against raltegravir-resistant HIV strains. As HIV has a very high mutational competence, the development of drugs with new mechanisms of inhibitory action and/or new active substituents may be a more successful route to take in the development of second- and third-generation IN inhibitors

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). Disease Control and Prevention: Using the BED HIV1 capture EIA assay to estimate incidence using STARHS in the context of surveillance in the United States.
  2. (2007). Family Foundation: The global HIV/AIDS epidemic. HIV/AIDS Policy Fact Sheet
  3. (1984). MA: Overview of HIV. Psychosom Med
  4. (2007). UNAIDS: AIDS epidemic update.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.